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Background: Improved understanding of the etiology of cognitive impairment is needed to 
develop effective preventive interventions. Higher amino-terminal pro-B-type natriuretic peptide 
(NT-proBNP) is a biomarker of cardiac dysfunction associated with risk cardiovascular diseases 
and stroke in apparently healthy people. 
Objective: To study the association of NT-proBNP with risk of incident cognitive impairment. 
Methods: The Reasons for Geographic and Racial Differences in Stroke is a national cohort 
study of 30,239 black and white Americans age 45 and older at baseline, enrolled in 2003-7. 
Among participants without prebaseline stroke or cognitive impairment, baseline NT-proBNP 
was measured in 470 cases of incident cognitive impairment and 557 controls. Cases were 
participants scoring below the 6th percentile of demographically-adjusted means on at least 2 of 
3 serially administered tests (word list learning, word list recall and semantic fluency) over 3.5 
years follow-up.  
Results: Adjusting for age, gender, race, region of residence, education and income there was 
an increased odds ratio of incident cognitive impairment with increasing NT-proBNP; 
participants in the 4th versus 1st quartile (>127 versus ≤33 pg/ml) had a 1.69-fold increased odds 
(95% CI 1.11-2.58). Adjustment for cardiovascular risk factors and presence of an 
apolipoprotein E4 allele had no substantial impact on the odds ratio. Results did not differ by 
age, race, gender or presence of an apolipoprotein E4 allele. 
Conclusion: Higher NT-pro-BNP was associated with incident cognitive impairment in this 
prospective study, independent of atherogenic and Alzheimer’s disease risk factors. Future work 
should clarify pathophysiologic connections of NT-proBNP and cognitive dysfunction. 
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Introduction 
Over 5 million people in the United States are cognitively impaired, and each year 12% of these 
will develop dementia[1]. As there are no effective treatments, identification of risk factors for 
cognitive impairment is crucial to developing prevention strategies[2]. Emerging evidence 
suggests that cardiovascular risk factors are related to increased risk of dementia[2, 3].  
 
N-terminal pro-B-type Natriuretic peptide (NT-proBNP) is a marker of cardiac function used in 
detection and monitoring of congestive heart failure. Higher NT-proBNP is also a risk marker for 
future stroke, coronary heart disease and atrial fibrillation[4-10]. Levels are higher with 
increasing age and in the presence of heart disease, atrial fibrillation and kidney disease[10]. 
Given the similar risk factors for vascular disease and cognitive impairment, and associations of 
heart failure and Framingham Stroke Risk Scale scores with cognitive impairment[11, 12], we 
hypothesized that higher NT-proBNP would be associated with risk of cognitive impairment. 
 
We addressed this hypothesis by studying the association of baseline NT-proBNP with risk of 
incident cognitive impairment using a nested case-control study design in the Reasons for 
Geographic and Racial Differences in Stroke (REGARDS) cohort study of 30,239 black and 
white Americans age 45 and older. 
 
Materials and Methods 
Participants 
The REGARDS cohort is a population-based cohort study investigating racial and geographic 
disparities in stroke and cognitive impairment[13]. The study enrolled 30,239 individuals age 45 
and older by telephone from 2003 to 2007. Blacks and residents of the stroke belt states of 
North Carolina, South Carolina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, and 
Arkansas were oversampled, with final proportions of 45% men, 55% women, 58% whites, 42% 
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blacks, 56% stroke belt residents and 44% non-stroke belt residents. Race was self-identified by 
participants. Demographic, socioeconomic factors, medical history and verbal informed consent 
were obtained by computer-assisted telephone interview.  At a subsequent in-home 
examination written informed consent, physical exam, blood samples, electrocardiogram (ECG), 
and medication inventory were obtained[13].  Study methods were reviewed and approved by 
Institutional Review Boards at each study institution.  
 
Measurements and Definitions 
Baseline cognitive status was determined with the Six-Item Screener (SIS; 3 temporal 
orientation items and delayed recall of 3 objects) which was validated in community and clinical 
samples including large numbers of black participants[14]. Scores are 0-6 with 4 or fewer 
correct indicating cognitive impairment. Hypertension was defined as systolic blood pressure 
≥140 mmHg, diastolic pressure ≥90 mmHg, or self-reported hypertension with use of anti-
hypertensive medications. Diabetes was defined by self-report with use of anti-diabetic 
medications, fasting glucose >126 mg/dL, or non-fasting glucose >200 mg/dL. Albuminuria was 
defined as urinary albumin to creatinine ratio >30 mg/g. Estimated glomerular filtration rate 
(eGFR) was calculated using the Chronic Kidney Disease (CKD) Epidemiology Collaboration 
formula, with CKD defined as eGFR <60 ml/min/1.73m2.[15] Left ventricular hypertrophy (LVH) 
was classified by centrally-read ECG. Atrial fibrillation was defined as self-report or presence on 
ECG. Prebaseline heart disease was defined as self-reported myocardial infarction, bypass, 
angioplasty or stenting, or myocardial infarction on ECG. Prebaseline stroke was defined by 
self-report of a physician diagnosis. Stroke after baseline was identified and validated as 
previously described[16]. 
 
Longitudinal Cognitive Assessment 
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Participants were contacted every 6 months to ascertain health status and conduct cognitive 
testing. Starting in 2006 a three test battery was performed every 2 years including Word List 
Learning, Word List Recall and Semantic Fluency (animals), all from the Consortium to 
Establish a Registry for Alzheimer’s Disease[17]. The Word List Learning score is the number of 
words recalled on a 10-item, three-trial word list learning task (range 0-30). Word List Recall is 
the number of words recalled after a filled delay (range 0-10). Semantic Fluency is the number 
of animals named in 60 seconds. All testing was supervised with quality control monitoring.  
 
Case Control Study Design 
A nested case control study was employed to select a subset of REGARDS participants for NT-
proBNP measurement and provide results approximating those obtained from NT-proBNP 
measurement in the entire cohort. Detailed methods were previously reported [18]. Briefly, after 
excluding participants with prevalent stroke (n=1930), cognitive impairment at baseline SIS 
(n=2,319), missing data (n=546), stroke prior to first SIS (n=28) or with insufficient follow-up 
cognitive testing at the time of sample selection (n=7786), we identified cases from the 
remaining 17,630 participants. Incident cognitive impairment was defined using an absolute 
score approach[19] that incorporated regression-based adjustment for age, education, race and 
gender on the three test cognitive battery. Incident cognitive impairment was defined as scores 
on 2 of 3 components of the most recently administered three test battery that were <6th 
percentile of each participant’s age, race and gender-predicted score. This identified 495 cases 
of incident cognitive impairment.  
 
Controls were selected from a cohort random sample of 1100 participants selected from the 
entire REGARDS cohort for a case-cohort study of stroke[10]. This sample was chosen at 
random within age, gender and race strata (50% black, 50% white, 50% women, 50% men, and 
age groups 20% 45-54, 20% 55-64, 25% 65-74, 25% 75-84, and 10% ≥85).  After exclusions 
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using the same criteria for cases, those with insufficient cognitive testing to determine case 
status, or who became a case, the control group included 587 participants[18]. We did not apply 
incidence density sampling to potential controls. 
 
Fasting baseline blood samples were drawn, processed, shipped to the University of Vermont, 
and stored[20]. NT-proBNP was measured in the case control sample using an 
electrochemiluminescence immunoassay (Roche Elecsys 2010; CV <5%). NT-proBNP was 
missing on 25 cases and 30 controls due to missing blood samples or technical issues leaving 
470 cases and 557 controls for analysis. Apolipoprotein E (ApoE) genotype was determined by 
TaqMan analysis of rs429358 and rs4712.  
 
Statistical Methods 
All analyses were weighted to account for the stratified selection of the controls. We calculated 
distributions of baseline characteristics (mean/SD or proportion) by case control status. To 
estimate relative risks, odds ratios and 95% confidence intervals for the association of NT-
proBNP concentration and cognitive impairment were calculated using weighted logistic 
regression. NT-proBNP was divided into quartiles based on the distribution in the control group, 
with the bottom quartile as the reference group. A p value for trend in odds ratios across 
quartiles was calculated using a linear contrast statement for quartiles within the SAS 
surveylogistic procedure. Four levels of adjustment were used to evaluate confounding based 
on known correlates of NT-proBNP and cognitive function. Model 1 included age, gender, race, 
region of residence, education and income. Model 2 added hypertension medication use, lipid 
levels, diabetes, systolic blood pressure, LVH, history of heart disease, atrial fibrillation, 
congestive heart failure status, alcohol use and physical activity.  Model 3 added eGFR and 
albuminuria. Model 4 added presence of at least one ApoE4 allele. Sensitivity analysis further 
adjusted for development of incident stroke during follow-up. Model 1 was used for interaction 
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testing to determine if associations of NT-proBNP quartiles with risk of cognitive impairment 
differed by age (as a continuous variable and in strata of 45-55, 55-70 and >70 years), race, 
gender, region of residence and presence of an ApoE4 allele. In the case of a cross product 
interaction term p-value of NT-proBNP quartile with any of these factors of <0.10, stratified 
analyses were performed. 
 
Results 
The median time from baseline to the most recent three test battery was 3.5 years among the 
470 cases and 557 controls. Table 1 shows associations of baseline risk factors with case-
control status. Because of the demographically-adjusted regression-based selection of cognitive 
impairment cases, cases and controls were similar by age, race, gender, and education. Cases 
were more likely than controls to reside in the stroke belt, have lower income, higher body-mass 
index, and to have diabetes, hypertension, kidney disease and cardiovascular conditions. They 
were more likely to smoke and less likely to have moderate or heavy alcohol use.  In controls 
the median NT-proBNP declined with increasing number of APOe4 alleles (71, 52, and 37 pg/ml 
for 0, 1 or 2 E4 alleles; p trend = 0.007). In cases these values were 84, 88, and 62 pg/ml; p 
trend = 0.68. 
 
Table 2 shows associations of NT-proBNP with risk of cognitive impairment. In Model 1, NT-
proBNP in the top compared to bottom quartile was associated with a 1.69-fold increased risk of 
cognitive impairment (95% CI 1.11-2.58). Associations did not change after additional 
adjustment for cardiovascular and lifestyle risk factors for cognitive impairment or with 
adjustment for presence of at least one ApoE4 allele (Models 2-4). The p-value for trend across 
quartiles was ≤0.01 in all models although there was a lower risk in the second quartile 
compared to the first that was not statistically significant. Sensitivity analysis adding adjudicated 
stroke during follow-up (n=34) to the final model had a small impact on the odds ratios (4th vs 1st 
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quartile odds ratio 1.56 (95% CI 0.92-2.64), p for trend across quartiles 0.02). Sensitivity 
analysis excluding participants with NT-proBNP above the manufacturer’s cutpoint for heart 
failure reduced the odds ratio for the top quartile modestly (for model 2: 1.59 (95% CI 0.93-
2.71); for model 3: 1.46 (95% CI 0.83-2.54); respective p for trend across quartiles 0.02 and 
0.05). 
 
Interaction testing revealed that the association of NT-proBNP with incident cognitive 
impairment only differed by region (p interaction 0.09). As shown in figure 1, this difference by 
region was driven by a regional difference in the magnitude of the association for the 3rd 
quartile. Interaction term p values for NT-proBNP with age, age strata, race, gender and 
presence of an ApoE4 allele were 0.78, 0.45, 0.16, 0.18 and 0.16, respectively.  
 
Discussion 
In this prospective observational study including black and white men and women aged 45 and 
older, baseline NT-proBNP concentration in the top compared to the bottom quartile was 
associated with a 1.6-fold increased risk of incident cognitive impairment. Findings were not 
explained by adjustment for a variety of factors including socio-demographic factors, 
cardiovascular and lifestyle factors, kidney function measures, occurrence of stroke during 
follow-up, or presence of an apoE4 allele (which was associated with lower NT-proBNP in 
controls but not cases). Findings suggest that the observed association reflects a 
pathophysiology relating NT-proBNP to cognitive impairment that is at least partly distinct from 
both atherosclerosis and Alzheimer’s disease, or that facilitates the clinical expression of pre-
existing brain pathology. Results were robust across several subgroups. Apparent differences in 
results by region were likely a chance finding based on the pattern of association observed.  
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Most previous research on associations of NT-proBNP with cognitive function reported cross-
sectional studies, while our study was prospective so can minimize issues of reverse causality 
of associations. A study of 56 patients with dementia and cardiovascular disease showed cross 
sectional correlations of BNP with the conceptualization subtest of the Dementia Rating Scale 
score[21]. In 1066 elderly type 2 diabetics, those with higher NT-proBNP had lower scores on a 
cognitive battery, but this association was confounded by vascular and diabetes-related risk 
factors[22]. In the Rancho Bernardo study, higher NT-pro-BNP was correlated with lower 
performance on the Mini-Mental State Examination (MMSE) and complex sequential tracking, 
but not a test of semantic fluency[23].  These associations were independent of other risk 
factors. Two biomarker discovery studies reported that NT-proBNP was associated with 
cognitive disorders[24, 25]. In one study, among 147 biomarkers, apoE genotype and NT-
proBNP were primary contributors to improved specificity for a diagnosis of Alzheimer’s 
Disease, but NT-proBNP was not associated with apoE genotype [25], contrary to findings here. 
In 4,029 older community-dwelling adults in Iceland, NT-proBNP was inversely associated with 
memory, processing speed and executive functioning, as well as lower brain volumes by 
magnetic resonance imaging; the associations with executive function and processing speed 
were independent of cardiac output[26].  
 
We are aware of four prospective studies on this topic. In the Alzheimer’s Disease 
Neuroimaging Initiative, biomarker panels including NT-proBNP did not distinguish progression 
from mild cognitive impairment to Alzheimer’s disease over 2 years[27]. In 464 Finnish subjects 
aged 75 and older, higher baseline NT-proBNP was associated with decline in the MMSE score 
and a 1.53-fold increased risk of dementia (with only 59 cases) over 5 years[28]. In the 
Rotterdam Study higher baseline NT-proBNP was associated with risk of future dementia and 
vascular dementia but not Alzheimer’s disease; the effect size was similar to the current report 
(HR 1.52, 95% CI 1.10-2.09 for NT-proBcNP in 4th vs 1st quartile)[29]. In that study higher NT-
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proBNP was associated longitudinally with declining information processing speed, but not with 
change in tests of attention, concentration, verbal fluency or executive function (memory testing 
was not done). In a Finnish cohort with 13.8 years of follow-up and dementia determined by 
administrative data, each SD higher baseline NT-prBNP was associated with a 1.3-fold higher 
risk of dementia, but not among women[30]. The current study adds to these studies by 
including a large national sample of US blacks and whites from a broad age range, and by 
including a large number of cases of incident cognitive impairment. Our findings differ in that we 
did not evaluate dementia as the outcome or changes in individual test scores. 
 
Mechanisms to explain an association of NT-proBNP with cognitive impairment are uncertain. 
Strong evidence links higher NT-proBNP with atherosclerotic diseases including stroke[5, 10] so 
atherosclerosis may be the connection. However, the lack of confounding by cardiovascular risk 
factors observed here, other findings relating NT-proBNP to cerebrospinal fluid Aβ42 level and t-
tau/Aβ42 ratios[24], and to improved diagnostic accuracy of apoE genotyping for cognitive 
disorders[25] suggests a direct effect of NT-proBNP on brain function. A mutation of atrial 
natriuretic peptide that is associated with vascular risk was also associated with higher NT-
proBNP levels, and leads to endothelial cell hyperpermeability, which might lead to 
atherosclerotic disease[31] or have other direct effects on brain function. Alternatively, NT-
proBNP may simply be a marker of cardiac dysfunction that directly or indirectly contributes to 
cognitive impairment[32]. The observed modest reduction of the odds ratio of cognitive 
impairment with higher NT-proBNP after excluding participants with NT-proBNP above the 
manufacturer’s cutpoint for heart failure suggests that a partial explanation for our findings could 
be the impact of unrecognized heart failure impacting cognitive impairment. However, it is also 
possible that levels of NT-proBNP in this range signify subclinical cardiac dysfunction of 
relevance, or other biologies underlying our findings. We do not have cardiac imaging data to 
further address this. 
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Strengths and limitations of this study warrant consideration. The prospective nested case 
control study design allowed us to efficiently address the research question while measuring 
NT-proBNP in a subsample rather than the entire cohort. The prospective study design 
minimized the likelihood of reverse causality as an Our rich data set allowed for adjustment for 
many important measured confounders. Our definition of cognitive impairment captured a 
clinically relevant level of impairment and had face validity given the previously reported 
associations of risk factors with impairment [18, 33], however we did not have evaluation for 
dementia or brain imaging, which are limitations of the study. Follow-up time was relatively 
short, which could be considered a weakness, but our large sample allowed accumulation of a 
large number of cases quickly with minimal attrition of participants. Use of the baseline SIS to 
identify baseline cognitive impairment allowed exclusion of participants with significant 
impairment but would have missed those with more subtle impairment. This would cause bias in 
our observed results to the null, thus reported associations might be underestimates. We did not 
have a measure of cardiac dysfunction such as an echocardiogram. Finally, use of a single 
measurement of NT-proBNP might lead to underestimation of the true risk of cognitive 
impairment with higher NT-proBNP. 
 
Results of this study and other research highlight important connections between NT-proBNP 
and cognitive impairment. Future studies should determine if interventions to improve cardiac 
function could preserve brain function. Findings also support pursuit of basic research on effects 
of natriuretic peptides on brain function.    
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Table 1. Baseline characteristics of cases and controls. 
 
* Data weighted to analytic cohort, total N=17,630 
Baseline Risk Factor Levels 
% unless otherwise specified 
Cases 
(N= 470) 
Controls 
(N=557)* 
p-value† 
Black Race  33 36 0.27 
Age, Mean 64.5 64.1 0.47 
Male Sex 41 43 0.63 
Education ≤ High school 34 31 0.43 
Stroke Belt Region 66 52 <0.001 
Income < $20,000 28 14 <0.001 
Diabetes Mellitus 29 18 <0.001 
Hypertension 62 56 0.07 
Dyslipidemia 60 58 0.46 
Atrial Fibrillation 10 9 0.74 
Left Ventricular Hypertrophy by ECG 11 7 0.02 
History of Heart Disease 21 13 0.003 
Congestive Heart Failure 20 13 0.004 
Current Smoker 17 12 0.03 
Heavy or Moderate Alcohol Use 30 40 0.002 
No weekly exercise 38 32 0.05 
BMI (kg/m2), mean 30.1 29.2 0.01 
Statin use  34 32 0.42 
eGFR <60 ml/min/1.73m2 14 6 <0.001 
Albuminuria, % 18 11 0.006 
Apolipoprotein E4 allele present 32 32 0.90 
18 
 
† Pearson chi square (corrected for survey design with the second-order correction of Rao and 
Scott); Wald F statistic for age and body-mass index.  
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Table 2. Odds Ratio of Cognitive Impairment by Baseline NT-proBNP 
 Quartile of NT-proBNP  
p for 
trend* 
 1 2 3 4 
5-33 pg/ml 33-57 pg/ml 57-127 pgml >127 pg/ml 
Model 1 1 (Ref) 0.66 (0.43-1.02) 1.30 (0.87-1.94) 1.69 (1.11-2.58) 0.001 
Model 2 1 (Ref) 0.73 (0.44-1.21) 1.42 (0.90-2.25) 1.85 (1.14-3.01) 0.002 
Model 3 1 (Ref) 0.76 (0.45-1.28) 1.41 (0.88-2.27) 1.67 (1.01-2.77) 0.01 
Model 4 1 (Ref) 0.76 (0.46-1.28) 1.50 (0.93-2.42) 1.62 (0.97-2.73) 0.01 
 
*trend across quartiles as an ordinal variable 1, 2, 3, 4. 
Model 1.  Adjusted for age, sex, race, region, education, income 
Model 2.  Adjusted for above + hypertension medication use, total and LDL cholesterol, 
diabetes, systolic blood pressure, left ventricular hypertrophy, alcohol use, physical activity, 
history of heart disease, atrial fibrillation, and congestive heart failure.  
Model 3.  Adjusted for above + estimated glomerular filtration rate and urinary 
albumin/creatinine.  
Model 4.  Adjusted for above + apolipoprotein e4 allele present 
Ref = reference group 
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Figure Title and Legend 
 
Figure. Association of Baseline NT-proBNP in Quartiles with Risk of Incident Cognitive 
Impairment by Region. Statistical testing for interaction suggested differences in the 
association of NT-proBNP with cognitive impairment by region but the figure shows that in 
stratified analyses these apparent differences had a pattern that was not of material importance. 
Stroke belt states are North Carolina, South Carolina, Georgia, Tennessee, Mississippi, 
Alabama, Louisiana, and Arkansas. 
 
 
